Low-Dose Aspirin Use Significantly Improves the Survival of Late-Stage NPC: A Propensity Score-Matched Cohort Study in Taiwan

Luo, Sheng‐Dean; Chen, Wei-Chih; Wu, Ching-Nung; Li, Shau-Hsuan; Fang, Fu‐Min; Huang, Tai‐Lin; Wang, Yu Ming; Chiu, Tai‐Jan; Wu, Shao-Chun

doi:10.3390/cancers12061551

Cited by 11 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For cancers other than colon, breast and prostate, the supplementary files list 'other' cancers: nasopharynx [96,102], GI cancers, including oropharynx, stomach, oesophagus and rectum, [41,88,97,106,121,124], liver [93,103], gallbladder in four parts [101], pancreas [125], bladder [98,112,114], ovary [81,[83][84][85][86]113], endometrium [87,89], head & neck [88, 90-92, 104, 123], lung [82,94,108,122], leukaemia [79], glioma [100], melanoma [99] and two [39,80] present a mixture of cancers. Not all the estimates of association in these reports of 'other' cancers are significant at p < 0.05.…”

Section: Mortalitymentioning

confidence: 99%

Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Elwood¹,

Morgan²,

Delon³

et al. 2021

ecancer

View full text Add to dashboard Cite

Background: Despite the accumulation of research papers on aspirin and cancer, there is doubt as to whether or not aspirin is an acceptable and effective adjunct treatment of cancer. The results of several randomised trials are awaited, and these should give clear evidence on three common cancers: colon, breast and prostate. The biological effects of aspirin appear likely however to be of relevance to cancer generally, and to metastatic spread, rather than just to one or a few cancers, and there is already a lot of evidence, mainly from observational studies, on the association between aspirin and survival in a wide range of cancers. Aims:In order to test the hypothesis that aspirin taking is associated with an increase in the survival of patients with cancer, we conducted a series of systematic literature searches to identify clinical studies of patients with cancer, some of whom took aspirin after having received a diagnosis of cancer.Results: Three literature searches identified 118 published observational studies in patients with 18 different cancers. Eighty-one studies report on aspirin and cancer mortality and 63 studies report on all-cause mortality. Within a total of about a quarter of a million patients with cancer who reported taking aspirin, representing 20%-25% of the total cohort, we found aspirin to be associated with a reduction of about 20% in cancer deaths (pooled hazard ratio (HR): 0.79; 95% confidence intervals: 0.73, 0.84 in 70 reports and a pooled odds ratio (OR): 0.67; 0.45, 1.00 in 11 reports) with similar reductions in all-cause mortality (HR: 0.80; 0.74, 0.86 in 56 studies and OR: 0.57; 0.36, 0.89 in seven studies). The relative safety of aspirin taking was examined in the studies and the corresponding author of every paper was written to asking for additional information on bleeding. As expected, the frequency of bleeding increased in the patients taking aspirin, Review

show abstract

Section: Mortalitymentioning

confidence: 99%

Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Elwood¹,

Morgan²,

Delon³

et al. 2021

ecancer

View full text Add to dashboard Cite

show abstract

“…In Smith [12], the breast cancer surveillance guidelines are discussed. We observe that the Kaplan-Meier method is universal and can be applied not only to the study of breast cancer treatment but also to other cancers to compare the survival of different groups of patients after diagnosis, see for instance [13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Actuarial Analysis of Survival among Breast Cancer Patients in Lithuania

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most common cause of mortality due to cancer for women both in Lithuania and worldwide. Chances of survival after diagnosis differ significantly depending on the stage of disease at the time of diagnosis. Extended term periods are required to estimate survival of, e.g., 15–20 years. Moreover, since mortality of the average population changes with time, estimates of survival of cancer patients derived after a long period of observation can become outdated and can be no longer used to estimate survival of patients who were diagnosed later. Therefore, it can be useful to construct analytic functions that describe survival probabilities. Shorter periods of observation can be enough for such construction. We used the data collected by the Lithuanian Cancer Registry for our analysis. We estimated the chances of survival for up to 5 years after patients were diagnosed with breast cancer in Lithuania. Then we found analytic survival functions which best fit the observed data. At the end of this paper, we provided some examples for applications and directions for further research. We used mainly the Kaplan–Meier method for our study.

show abstract

“…A meta-analysis demonstrates that aspirin use confers a survival benefit in a dose-dependent manner, with a higher dosage of aspirin producing a greater reduction in the risk of colorectal cancer 31 . In addition, aspirin use has also shown benefits in reducing cancer in a duration-dependent manner across various cancers 17 , 32 – 34 . In our study, low-dose aspirin (100 mg/day) was prescribed and taken by patients after diagnosis of OSCC.…”

Section: Discussionmentioning

confidence: 99%

Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

Luo

Chen

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.

show abstract

Low-Dose Aspirin Use Significantly Improves the Survival of Late-Stage NPC: A Propensity Score-Matched Cohort Study in Taiwan

Cited by 11 publications

References 41 publications

Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Actuarial Analysis of Survival among Breast Cancer Patients in Lithuania

Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

Contact Info

Product

Resources

About